Table 2.
Tumor response
| Response | Total(N = 34) | TQB2450 1200 mg +anlotinib 10 mg (N = 3) | TQB2450 1200 mg +anlotinib 12 mg (N = 31) |
|---|---|---|---|
| Best response, n (%) | |||
| CR | 3 (8.8) | 1 (33.3) | 2 (6.5) |
| PR | 6 (17.6) | 1 (33.3) | 5 (16.1) |
| SD | 16 (47.1) | 0 | 16 (51.6) |
| PD | 7 (20.6) | 1 (33.3) | 6 (19.4) |
| NE | 2 (5.9) | 0 | 2 (6.5) |
| ORR, % (95% CI) | 26.5 (12.9, 44.4) | 66.7 (9.4, 99.2) | 22.6 (9.6, 41.1) |
| DCR, % (95% CI) | 73.5 (55.6, 87.1) | 66.7 (9.4, 99.2) | 74.2 (55.4, 88.1) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; CI, confidence interval; DCR, disease control rate. ORR and DCR were summarized with descriptive statistics. The 95% confidence intervals (CIs) of ORR and DCR were calculated using the Clopper-Pearson method.